Genomic characterization of metastatic breast cancers.

Bertucci, François; Ng, Kiu Yan Charlotte; Patsouris, Anne; Droin, Nathalie; Piscuoglio, Salvatore; Carbuccia, Nadine; Soria, Jean Charles; Dien, Alicia Tran; Adnani, Yahia; Kamal, Maud; Garnier, Séverine; Meurice, Guillaume; Jimenez, Marta; Dogan, Semih; Verret, Benjamin; Chaffanet, Max; Bachelot, Thomas; Campone, Mario; Lefeuvre, Claudia; Bonnefoi, Herve; ... (2019). Genomic characterization of metastatic breast cancers. Nature, 569(7757), pp. 560-564. Springer Nature 10.1038/s41586-019-1056-z

[img] Text
s41586-019-1056-z.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (7MB) | Request a copy

Metastasis is the main cause of death for patients with breast cancer. Many studies have characterized the genomic landscape of breast cancer during its early stages. However, there is evidence that genomic alterations are acquired during the evolution of cancers from their early to late stages, and that the genomic landscape of early cancers is not representative of that of lethal cancers1-7. Here we investigated the landscape of somatic alterations in 617 metastatic breast cancers. Nine driver genes (TP53, ESR1, GATA3, KMT2C, NCOR1, AKT1, NF1, RIC8A and RB1) were more frequently mutated in metastatic breast cancers that expressed hormone receptors (oestrogen and/or progesterone receptors; HR+) but did not have high levels of HER2 (HER2-; n = 381), when compared to early breast cancers from The Cancer Genome Atlas. In addition, 18 amplicons were more frequently observed in HR+/HER2- metastatic breast cancers. These cancers showed an increase in mutational signatures S2, S3, S10, S13 and S17. Among the gene alterations that were enriched in HR+/HER2- metastatic breast cancers, mutations in TP53, RB1 and NF1, together with S10, S13 and S17, were associated with poor outcome. Metastatic triple-negative breast cancers showed an increase in the frequency of somatic biallelic loss-of-function mutations in genes related to homologous recombination DNA repair, compared to early triple-negative breast cancers (7% versus 2%). Finally, metastatic breast cancers showed an increase in mutational burden and clonal diversity compared to early breast cancers. Thus, the genomic landscape of metastatic breast cancer is enriched in clinically relevant genomic alterations and is more complex than that of early breast cancer. The identification of genomic alterations associated with poor outcome will allow earlier and better selection of patients who require the use of treatments that are still in clinical trials. The genetic complexity observed in advanced breast cancer suggests that such treatments should be introduced as early as possible in the disease course.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)

UniBE Contributor:

Ng, Kiu Yan Charlotte


600 Technology > 610 Medicine & health




Springer Nature




Marla Rittiner

Date Deposited:

23 Dec 2019 13:30

Last Modified:

05 Dec 2022 15:33

Publisher DOI:


PubMed ID:





Actions (login required)

Edit item Edit item
Provide Feedback